We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Genus plc (GNS) Ordinary 10p

Sell:1,730.00p Buy:1,734.00p 0 Change: 16.00p (0.93%)
FTSE 250:0.50%
Market closed Prices as at close on 4 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Ex-dividend
Sell:1,730.00p
Buy:1,734.00p
Change: 16.00p (0.93%)
Market closed Prices as at close on 4 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Ex-dividend
Sell:1,730.00p
Buy:1,734.00p
Change: 16.00p (0.93%)
Market closed Prices as at close on 4 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Ex-dividend
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Genus plc is a United Kingdom-based animal protein genetics company. The Company supplies breeding animals with desirable characteristics for farmers, enabling them to produce quality meat and milk. Its segments include Genus PIC, Genus ABS and Genus Research and Development. The Genus PIC segment is engaged in the porcine sales business. The Genus ABS segment is engaged in the bovine sales business. Its bovine genetics business sells dairy and beef bull semen and embryos from its superior cattle, which are sold to farmers to breed their cows through artificial insemination. Its porcine genetics business sells genetically superior breeding pigs and semen to farmers, so they can breed commercial pigs with desirable characteristics for pork production. It also provides technical services and advice to farmers, to maximize the performance of its breeding animals in their farms. The Company has supply chain and distribution networks in over 80 countries.

Contact details

Address:
Matrix House, Basing View
BASINGSTOKE
RG21 4DZ
United Kingdom
Telephone:
+44 (01256) 347100
Website:
https://www.genusplc.com

Important dates

Future events
Interim results 27 February 2025 27/02/25
Final dividend payment date 06 December 2024 06/12/24
Past events
AGM 20 November 2024 20/11/24
Trading Announcement 20 November 2024 20/11/24
Final ex-dividend date 07 November 2024 07/11/24
Annual report 14 October 2024 14/10/24
Final results 05 September 2024 05/09/24
Interim dividend payment date 28 March 2024 28/03/24
Interim ex-dividend date 29 February 2024 29/02/24
Interim results 22 February 2024 22/02/24
Trading Announcement 15 February 2024 15/02/24
Final dividend payment date 08 December 2023 08/12/23

General stock information

EPIC:
GNS
ISIN:
GB0002074580
Market cap:
£1.14 billion
Shares in issue:
65.69 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE techMARK 100,FTSE 250,FTSE 350,FTSE All Share,FTSE techMARK All Share

Key personnel

  • Jorgen Kokke
    Chief Executive Officer, Executive Director
  • Alison Henriksen
    Chief Financial Officer, Executive Director
  • Matt Culbertson
    Chief Operating Officer
  • Angelle Rosata
    Chief Human Resource Officer
  • Elena Rice
    Chief Scientific Officer and Head of Research and Development
  • Dan Hartley
    Group General Counsel and Company Secretary
  • Jim Low
    Chief Operating Officer of Genus ABS
  • Jerry Thompson
    Regional Director - ABS EMEA

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.